What we’ve learned from the first EU joint clinical assessments: Takeaways from a panel of RWE and HTA experts
One Standard, Many Markets: What FDA, EMA, and PMDA Actually Agree On
.png)
ASCO 2026: Translating oncology innovation into real-world impact
Rewriting the real-world evidence playbook for clinical development
ISPOR 2026 reflections: AI, access, and the evolving role of RWE in oncology
From innovation to strategic insight: making sense of rapid advances in bladder cancer care
Unlocking the next level of RWD: Flatiron’s Scientific Vision
